XTX Topco Ltd lowered its position in shares of PDS Biotechnology Co. (NASDAQ:PDSB – Free Report) by 67.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,654 shares of the company’s stock after selling 40,600 shares during the quarter. XTX Topco Ltd owned approximately 0.05% of PDS Biotechnology worth $58,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Kathleen S. Wright Associates Inc. bought a new stake in PDS Biotechnology during the 1st quarter worth about $28,000. Tempus Wealth Planning LLC bought a new position in shares of PDS Biotechnology in the 2nd quarter valued at about $55,000. Ground Swell Capital LLC bought a new position in shares of PDS Biotechnology in the 2nd quarter valued at about $67,000. Blair William & Co. IL boosted its stake in shares of PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after purchasing an additional 81,743 shares during the last quarter. Finally, Inspirion Wealth Advisors LLC boosted its stake in shares of PDS Biotechnology by 5.5% in the 1st quarter. Inspirion Wealth Advisors LLC now owns 354,977 shares of the company’s stock valued at $1,406,000 after purchasing an additional 18,383 shares during the last quarter. Institutional investors own 26.84% of the company’s stock.
PDS Biotechnology Stock Performance
Shares of NASDAQ:PDSB opened at $4.11 on Thursday. The company has a market capitalization of $150.75 million, a price-to-earnings ratio of -3.02 and a beta of 1.88. The firm’s 50 day simple moving average is $3.25 and its 200 day simple moving average is $3.35. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84. PDS Biotechnology Co. has a fifty-two week low of $2.53 and a fifty-two week high of $6.85.
Analyst Ratings Changes
Several research analysts have recently issued reports on PDSB shares. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a research note on Wednesday. B. Riley reduced their target price on shares of PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, June 12th. Finally, Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, PDS Biotechnology has an average rating of “Moderate Buy” and an average price target of $14.25.
Read Our Latest Stock Analysis on PDSB
About PDS Biotechnology
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
Featured Stories
- Five stocks we like better than PDS Biotechnology
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- What to Know About Investing in Penny Stocks
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Want to see what other hedge funds are holding PDSB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PDS Biotechnology Co. (NASDAQ:PDSB – Free Report).
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.